Show simple item record

dc.contributor.authorNorman, Jane Elizabeth
dc.contributor.authorMarlow, Neil
dc.contributor.authorMessow, Claudia-Martina
dc.contributor.authorShennan, Andrew
dc.contributor.authorBennett, Phillip R.
dc.contributor.authorThornton, Steven
dc.contributor.authorRobson, Stephen C.
dc.contributor.authorMcConnachie, Alex
dc.contributor.authorPetrou, Stavros
dc.contributor.authorSebire, Neil J.
dc.contributor.authorLavender, Tina
dc.contributor.authorWhyte, Sonia
dc.contributor.authorNorrie, John
dc.contributor.authorOPPTIMUM study group
dc.date.accessioned2016-06-20T12:40:02Z
dc.date.available2016-06-20T12:40:02Z
dc.date.issued2016-05
dc.identifier.citationNorman , J E , Marlow , N , Messow , C-M , Shennan , A , Bennett , P R , Thornton , S , Robson , S C , McConnachie , A , Petrou , S , Sebire , N J , Lavender , T , Whyte , S , Norrie , J & OPPTIMUM study group 2016 , ' Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study) : a multicentre, randomised, double-blind trial ' The Lancet , vol. 387 , no. 10033 , pp. 2106-2116 . DOI: 10.1016/S0140-6736(16)00350-0en
dc.identifier.issn0140-6736
dc.identifier.otherPURE: 63639519
dc.identifier.otherPURE UUID: 136ec661-6deb-4c9d-8dc9-3f728f573959
dc.identifier.otherPubMed: 26921136
dc.identifier.otherScopus: 84959111461
dc.identifier.urihttp://hdl.handle.net/2164/6135
dc.descriptionAcknowledgments We thank the members of the Trial Steering and Data Monitoring Committee and all the people who helped in the conduct of the study (including the OPPTIMUM collaborative group and other clinicians listed in the appendix). We are grateful to Paul Piette (Besins Healthcare Corporate, Brussels, Belgium) and Besins Healthcare for their kind donation of active and placebo drug for use in the study, and to staff of the pharmacy and research and development departments of the participating hospitals. We are also grateful to the many people who helped in this study but who we have been unable to name, and in particular all the women (and their babies) who participated in OPPTIMUM. OPPTIMUM was funded by the Efficacy and Mechanism Evaluation (EME) Programme, a Medical Research Council (MRC) and National Institute of Health Research (NIHR) partnership, award number G0700452, revised to 09/800/27. The EME Programme is funded by the MRC and NIHR, with contributions from the Chief Scientist Office in Scotland and National Institute for Social Care and Research in Wales. The views expressed in this publication are those of the author(s) and not necessarily those of the MRC, National Health Service, NIHR, or the Department of Health. The funder had no involvement in data collection, analysis or interpretation, and no role in the writing of this manuscript or the decision to submit for publication.en
dc.format.extent11en
dc.language.isoeng
dc.relation.ispartofThe Lanceten
dc.rightsCopyright © Norman et al. Open Access article distributed under the terms of CC BY. http://creativecommons.org/licenses/by/4.0/en
dc.subjectR Medicineen
dc.subjectMedical Research Council (MRC)en
dc.subjectG0700452en
dc.subjectNational Institute for Health Research (NIHR)en
dc.subject09/800/27en
dc.subjectChief Scientist Office (CSO)en
dc.subject.lccRen
dc.titleVaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study) : a multicentre, randomised, double-blind trialen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen, Health Services Research Uniten
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1016/S0140-6736(16)00350-0


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record